重组人血小板生成素联合糖皮质激素治疗原发性免疫性血小板减少症临床疗效分析
投稿时间:2014-05-16  修订日期:2014-05-28  点此下载全文
引用本文:胡丽,白燕,唐韫,黄杰.重组人血小板生成素联合糖皮质激素治疗原发性免疫性血小板减少症临床疗效分析[J].医学研究杂志,2015,44(11):125-128
DOI: 10.11969/j.issn.1673-548X.2015.11.035
摘要点击次数: 1248
全文下载次数: 866
作者单位E-mail
胡丽 611230 崇州市人民医院血液科  
白燕 611230 崇州市人民医院血液科 baiyansc@163.com 
唐韫 610041 成都, 华西医科大学第一附属医院血液科  
黄杰 610041 成都, 华西医科大学第一附属医院血液科  
中文摘要:目的 分析重组人血小板生成素(recombinant human thrombopoietin,rhTPO)联合糖皮质激素治疗原发性免疫性血小板减少症(primary immune thrombocytopenia,ITP)的疗效和安全性。方法 本研究采用回顾性研究方法,回顾性分析2013年1月~2014年1月崇州市人民医院血液科收治的68例原发性ITP患者的病例资料,根据患者的用药情况分为试验组和对照组,每组34例。试验组给予rhTPO联合糖皮质激素治疗,对照组给予糖皮质激素治疗,对比分析两组的疗效、安全性和不良反应。结果 经治疗后,试验组完全反应20例,有效10例,无效4例;对照组完全反应10例,有效12例,无效12例。试验组有效率为88.24%,对照组有效率64.71%,两组有效率差异具有统计学意义(χ2=5.23,P=0.020)。此外,治疗后试验组血小板水平(134.87±66.69)×109/L高于对照组(76.30±70.93)×109/L,差异具有统计学意义(t=3.32,P=0.002)。试验组血小板开始上升时间、血小板计数≥ 50×109/L时间(5.05±1.26,8.79±2.21d)均早于对照组(8.31±2.01,13.68±2.43d),差异具有统计学意义(t=8.01,P=0.000;t=8.68,P=0.000)。在安全性方面,治疗前后两组在血红蛋白、白细胞计数、肝功能(ALT、TBil)、肾功能(Cr、BUN)的差异均无统计学意义。两组的不良反应发生率差异也无统计学意义(χ2=0.41,P=0.53)。结论 rhTPO联合糖皮质激素治疗ITP患者的效果优于单用糖皮质激素治疗,其疗效和安全性是肯定的。
中文关键词:原发性免疫性血小板减少  重组人血小板生成素  糖皮质激素  疗效
 
A Clinical Efficacy Study of Primary Immune Thrombocytopenia by Recombinant Human Thrombopoietin Combined with Glucocorticoid.
Abstract:Objective To analyze the efficacy and safety of recombinant human thrombopoietin(rhTPO) combined with glucocorticoids in the treatment of primary immune thrombocytopenia(ITP). Methods A retrospective studyed was adopt in this paper. We retrospectively analyzed 68 cases with primary ITP patients in Chongzhou City People's Hospital from January 2013 to January 2014. The patients were divided to trial group and control group according to the use of the medication and 34 cases in each group. The trial group was treated with rhTPO combined with glucocorticoid and the control group was treated with glucocorticoid treatment only. And to comparative analysis the efficacy, safety and side effects between the two groups. Results After treatment, there were 20 cases complete response, 10 cases effective and 4 cases not effective in trial group while 10 cases complete response, 12 cases effective and 12 cases not effective in control group. The efficiency of trial group was 88.24% while the control group was 64.71%, and the efficiency of the two groups had a statistically significant difference(χ2=5.23,P=0.020). In addition, after treatment, the platelet levels were higher in trial group(134.87±66.69) ×109/L than in control group(76.30±70.93) ×109/L, the difference was statistically significant(t=3.32, P=0.002).The time of began to rise platelet, platelet count ≥ 50×109/L in trial group(5.05±1.26, 8.79±2.21d) were all earlier than in the control group(8.31±2.01, 13.68±2.43d), and the difference was statistically significant(t=8.01, P=0.000; t=8.68, P=0.000).In terms of security, there was no significant difference in hemoglobin levels, white blood cell counts, liver function(ALT, TBil), renal function(Cr, BUN) before and after treatment. The incidences of adverse events were also no statistically significant difference(χ2=0.41,P=0.530). Conclusion For patients with primary ITP, the efficacy of rhTPO combined with glucocorticoid is better than that single used glucocorticoid. Its efficacy and safety is for sure.
keywords:Primary immune thrombocytopenia  Recombinant human thrombopoietin  Glucocorticoids  Curative effect
查看全文  查看/发表评论  下载PDF阅读器

京公网安备 11010502037822号